Technology
Roche Revisits Dyno for AAV Technology with $50M Upfront Payment
Roche, Dyno Therapeutics, AAV technology, gene therapy, neurological diseases, strategic partnership
Prime Medicine Partners with Bristol Myers Squibb in $3.5B Cell Therapy Deal, Narrows Pipeline Focus
Prime Medicine, Bristol Myers Squibb (BMS), Cell Therapy, Gene Editing, Prime Editing, PASSIGE Technology, Ex Vivo T-Cell Therapies, Pipeline Reprioritization, Strategic Collaboration
Novo Nordisk Partners with NanoVation in $600M Deal for Advanced Genetic Medicine Delivery
Novo Nordisk, NanoVation Therapeutics, Genetic Medicine, Lipid Nanoparticle (LNP) Technology, Cardiometabolic Diseases, Rare Genetic Disorders
Roche Secures FDA Approval for Subcutaneous Tecentriq Hybreza, Enhancing Cancer Treatment Options
Roche, FDA Approval, Tecentriq Hybreza, Subcutaneous Administration, Cancer Immunotherapy, PD-L1 Inhibitor, Halozyme Therapeutics, Enhanze Drug Delivery Technology
Highlander Health: Revolutionizing Clinical Research with Integrated Solutions
Highlander Health, clinical research, personalized healthcare, evidence generation, technology enablement, Amy Abernethy, Brad Hirsch, Verily, FDA.
Enhancing Flu Vaccine Manufacturing and Supply: A Comprehensive Overview
Flu Vaccine Manufacturing, Supply Chain Reliability, Influenza Vaccine Production, Vaccine Manufacturing Technologies, Pandemic Preparedness
WCLC24: Merck & Daiichi Sankyo’s ADC Shows Promising Results in Small Cell Lung Cancer
WCLC24, Merck & Co., Daiichi Sankyo, ADC (Antibody Drug Conjugate), SCLC (Small Cell Lung Cancer), Ifinatamab Deruxtecan, DXd ADC Technology
Promising Phase 2 Results for Ifinatamab Deruxtecan in Small Cell Lung Cancer
Ifinatamab Deruxtecan, Small Cell Lung Cancer, Phase 2 Trial, ADC Technology, Daiichi Sankyo, Merck
Embracing Agility: Critical for the Role of QARA Professional
QARA Professional, Agility, Quality Assurance, Regulatory Affairs, Market Access, Innovative Therapeutic Solutions, AI, Technology, Regulatory Strategy, Leadership, Communication, Diversity, Inclusion.
Novo Nordisk Acquires 2seventy’s Gene Editing Technology and Haemophilia Candidate for $40 Million
Novo Nordisk, 2seventy, gene editing, haemophilia, MegaTAL, in vivo gene editing technology